Christopher J Coughlin
CIK 1110750 · EVP and CFO · last filed 2026-09-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CNC | Director | 49,347 | $70.24 | $3.47M | $0 | 3 | 2026-09-30 |
| CNTE | Director | 48,202 | — | — | $1.50M | 25 | 2026-05-13 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Director | 0 | $329.83 | $0 | $0 | 6 | 2024-03-18 |
| PBH | Director | 13,218 | $47.92 | $633.4K | $0 | 4 | 2022-08-03 |
| Allergan plc (AGN) Delisted | Director | 16,542 | — | — | $3.54M | 14 | 2020-05-11 |
| DUN & BRADSTREET CORP/NW (DNB) Delisted | Director | 17,335 | $9.15 | $158.6K | -$740.5K | 76 | 2017-03-13 |
| HOLOGIC INC (HOLX) Delisted | Director | 5,427 | $76.01 | $412.5K | $0 | 2 | 2017-03-09 |
| ACT | Director | 2,000 | $45.65 | $91.3K | $0 | 1 | 2015-06-08 |
| Covidien plc (COV) Delisted | Director | 58,032 | — | — | -$2.23M | 36 | 2014-03-21 |
| PLx Pharma Inc. (DPRX) Delisted | Director | 13,664 | — | — | $25.0K | 1 | 2014-03-20 |
| Forest Laboratories, LLC (FRX) Delisted | Director | 3,933 | $12.00 | $47.2K | $0 | 3 | 2013-08-16 |
| Johnson Controls International plc (TYC) Delisted | EVP and CFO | 84,573 | — | — | $0 | 7 | 2010-11-30 |
Recent Filings · Page 2 of 21
201 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-17 | CNTE | Buy (P) | +10,000 | $594.4K | EDGAR |
| 2024-10-02 | CNTE | Grant (A) | +402 | $0 | EDGAR |
| 2024-07-02 | CNTE | Grant (A) | +452 | $0 | EDGAR |
| 2024-05-24 | CNC | Notice (144) | −878 | -$67.4K | EDGAR |
| 2024-05-24 | CNTE | Sell (S) | −878 | -$67.4K | EDGAR |
| 2024-05-16 | CNTE | Grant (A) | +2,916 | $0 | EDGAR |
| 2024-04-02 | CNTE | Grant (A) | +388 | $0 | EDGAR |
| 2024-03-18 | Karuna Therapeutics, Inc. (KRTX) Delisted | Disp (D) | −990 | -$326.7K | EDGAR |
| 2024-01-03 | CNTE | Grant (A) | +502 | $0 | EDGAR |
| 2023-10-03 | CNTE | Grant (A) | +544 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.